Association of CDKN2A Homozygous deletion with clinicopathologic and immunological parameters in melanoma

Yasemin Çakır; Banu Lebe

doi:10.18614/dehm.1855297

Association of CDKN2A Homozygous deletion with clinicopathologic and immunological parameters in melanoma

Abstract

Objective of Study: We aimed to investigate the association between the presence of CDKN2A homozygous deletion and clinicopathological features and survival in melanomas, by using TCGA (Cancer Genome Atlas) data. In addition, we examined the correlation with immune cell infiltrations. Methods: Clinicopathologic parameters and survival times were compared between patients with and without CDKN2A homozygous deletion using the ‘TCGA, Firehose Legacy’ dataset on the Cbioportal website (www.cbioportal.org). Immune cell infiltration analyses were performed using the TIMER database (http://timer.comp-genomics.org/timer/). p<0.05 was considered statistically significant. Results: Patients with CDKN2A homozygous deletion had earlier age at diagnosis, thinner Breslow thickness, earlier T stage, lower metastatic rate and the presence of ulceration (p<0.05). Disease-free survival was shorter in patients with CDKN2A deletion (median: 56.83 and 49.21 months, p=0.01), whereas there was no significant difference in overall survival between the two groups (p>0.05). Analysis of the TIMER database revealed a negative correlation between the presence of CDKN2A homozygous deletion and CD4 positive T lymphocyte, B lymphocyte and dendritic cell infiltration, while there was a positive correlation between macrophage infiltration (p<0.05). Conclusions: We found a significant correlation between CDKN2A homozygous deletion and prognostic parameters such as tumor stage, metastasis, Breslow thickness and presence of ulceration as well as disease-free survival time. The significant correlation between CDKN2A loss and various immune cell infiltrations suggests that CDKN2A gene is involved in the shaping of tumor microenvironment and tumor immunity.

Keywords

Supporting Institution

No support

Ethical Statement

Not applicable

References

1. Piepkorn M. Melanoma genetics: an update with focus on the CDKN2A(p16)/ARF tumor suppressors. J Am Acad Dermatol. 2000 May;42(5 Pt 1):705–22; quiz 723–6. PubMed PMID: 10775844.
2. Cachia AR, Indsto JO, McLaren KM, Mann GJ, Arends MJ. CDKN2A mutation and deletion status in thin and thick primary melanoma. Clin Cancer Res. 2000 Sep;6(9):3511–5. PubMed PMID: 10999737.
3. Kreuger IZM, Slieker RC, van Groningen T, van Doorn R. Therapeutic Strategies for Targeting CDKN2A Loss in Melanoma. J Invest Dermatol. 2023 Jan;143(1):18-25.e1. PubMed PMID: 36123181.
4. Tran TP, Titus-Ernstoff L, Perry AE, Ernstoff MS, Newsham IF. Alteration of chromosome 9p21 and/or p16 in benign and dysplastic nevi suggests a role in early melanoma progression (United States). Cancer Causes Control. 2002 Sep;13(7):675–82. PubMed PMID: 12296515.
5. Zheng C, Sarin KY. Unveiling the genetic landscape of hereditary melanoma: From susceptibility to surveillance. Cancer Treat Res Commun. 2024;40:100837. PubMed PMID: 39137473.
6. Trembath DG, Ivanova A, Krauze MT, Kirkwood JM, Nikolaishvilli-Feinberg N, Moschos SJ. Melanoma-specific expression of the tumor suppressor proteins p16 and PTEN is a favorable prognostic factor in established melanoma brain metastases. Melanoma Res. 2021 Jun 1;31(3):264–7. PubMed PMID: 33871399; PubMed Central PMCID: PMC8086752.
7. Castaneda CA, Castillo M, Torres-Cabala C, Bernabe LA, Casavilca S, Villegas V, et al. Relationship between tumor-associated immune infiltrate and p16 staining over clinicopathological features in acral lentiginous melanoma. Clin Transl Oncol. 2019 Sep;21(9):1127–34. PubMed PMID: 30778854.
8. Gao J, Aksoy BA, Dogrusoz U, Dresdner G, Gross B, Sumer SO, et al. Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal. 2013 Apr 2;6(269):pl1. PubMed PMID: 23550210; PubMed Central PMCID: PMC4160307.

9. Cerami E, Gao J, Dogrusoz U, Gross BE, Sumer SO, Aksoy BA, et al. The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data. Cancer Discovery. 2012 May 1;2(5):401–4.
10. Li T, Fan J, Wang B, Traugh N, Chen Q, Liu JS, et al. TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. Cancer Research. 2017 Nov 1;77(21):e108–10.
11. Li T, Fu J, Zeng Z, Cohen D, Li J, Chen Q, et al. TIMER2.0 for analysis of tumor-infiltrating immune cells. Nucleic Acids Research. 2020 Jul 2;48(W1):W509–14.
12. Koynova D, Jordanova E, Kukutsch N, Van Der Velden P, Toncheva D, Gruis N. Increased C-MYC copy numbers on the background of CDKN2A loss is associated with improved survival in nodular melanoma. J Cancer Res Clin Oncol. 2007 Feb;133(2):117–23.
13. Sini MC, Manca A, Cossu A, Budroni M, Botti G, Ascierto PA, et al. Molecular alterations at chromosome 9p21 in melanocytic naevi and melanoma. Br J Dermatol. 2008 Feb;158(2):243–50. PubMed PMID: 18028495.
14. Conway C, Beswick S, Elliott F, Chang Y, Randerson‐Moor J, Harland M, et al. Deletion at chromosome arm 9p in relation to BRAF / NRAS mutations and prognostic significance for primary melanoma. Genes Chromosomes & Cancer. 2010 May;49(5):425–38.
15. Lade-Keller J, Riber-Hansen R, Guldberg P, Schmidt H, Hamilton-Dutoit SJ, Steiniche T. Immunohistochemical analysis of molecular drivers in melanoma identifies p16 as an independent prognostic biomarker. J Clin Pathol. 2014 Jun;67(6):520–8. PubMed PMID: 24607493.
16. Rowe CJ, Tang F, Hughes MCB, Rodero MP, Malt M, Lambie D, et al. Molecular markers to complement sentinel node status in predicting survival in patients with high-risk locally invasive melanoma: Molecular predictors of survival in melanoma. Int J Cancer. 2016 Aug 1;139(3):664–72.
17. Zhu Z, Song H, Xu J. CDKN2A Deletion in Melanoma Excludes T Cell Infiltration by Repressing Chemokine Expression in a Cell Cycle-Dependent Manner. Front Oncol. 2021 Mar 25;11:641077.

Details

Primary Language

English

Subjects

Pathology

Journal Section

Research Article

Authors

Yasemin Çakır ^*
0000-0002-1394-6474
Türkiye

Banu Lebe
0000-0003-2520-2665
Türkiye

Publication Date

July 30, 2026

Submission Date

January 3, 2026

Acceptance Date

June 25, 2026

Published in Issue

Year 2026 Volume: 40 Number: 3

DOI

https://doi.org/10.18614/dehm.1855297

IZ

https://izlik.org/JA52JJ42ND

Cite

RIS / Bibtex

APA

Çakır, Y., & Lebe, B. (2026). Association of CDKN2A Homozygous deletion with clinicopathologic and immunological parameters in melanoma. Developments and Experiments in Health and Medicine, 40(3), 367-377. https://doi.org/10.18614/dehm.1855297

AMA

1.Çakır Y, Lebe B. Association of CDKN2A Homozygous deletion with clinicopathologic and immunological parameters in melanoma. Dev Exp Health Med. 2026;40(3):367-377. doi:10.18614/dehm.1855297

Chicago

Çakır, Yasemin, and Banu Lebe. 2026. “Association of CDKN2A Homozygous Deletion With Clinicopathologic and Immunological Parameters in Melanoma”. Developments and Experiments in Health and Medicine 40 (3): 367-77. https://doi.org/10.18614/dehm.1855297.

EndNote

Çakır Y, Lebe B (July 1, 2026) Association of CDKN2A Homozygous deletion with clinicopathologic and immunological parameters in melanoma. Developments and Experiments in Health and Medicine 40 3 367–377.

IEEE

[1]Y. Çakır and B. Lebe, “Association of CDKN2A Homozygous deletion with clinicopathologic and immunological parameters in melanoma”, Dev Exp Health Med, vol. 40, no. 3, pp. 367–377, July 2026, doi: 10.18614/dehm.1855297.

ISNAD

Çakır, Yasemin - Lebe, Banu. “Association of CDKN2A Homozygous Deletion With Clinicopathologic and Immunological Parameters in Melanoma”. Developments and Experiments in Health and Medicine 40/3 (July 1, 2026): 367-377. https://doi.org/10.18614/dehm.1855297.

JAMA

1.Çakır Y, Lebe B. Association of CDKN2A Homozygous deletion with clinicopathologic and immunological parameters in melanoma. Dev Exp Health Med. 2026;40:367–377.

MLA

Çakır, Yasemin, and Banu Lebe. “Association of CDKN2A Homozygous Deletion With Clinicopathologic and Immunological Parameters in Melanoma”. Developments and Experiments in Health and Medicine, vol. 40, no. 3, July 2026, pp. 367-7, doi:10.18614/dehm.1855297.

Vancouver

1.Yasemin Çakır, Banu Lebe. Association of CDKN2A Homozygous deletion with clinicopathologic and immunological parameters in melanoma. Dev Exp Health Med. 2026 Jul. 1;40(3):367-7. doi:10.18614/dehm.1855297